Abbott today announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Under the terms of the agreement, Abbott will acquire all outstanding equity of IDEV Technologies for $310 million net of cash and debt.
The Federal Bureau of Investigation snagged $4 million in settlements with two clinics and a Michigan cardiologist accused of performing unnecessary cardiac surgeries. Federal investigators accused Dr. Jashu Patel and his Jackson Cardiology Associates practice as well as Allegiance Health of subjecting patients "to invasive and potentially harmful procedures" that led to at least one patient's death.
By adapting a programmable device used to manufacture integrated circuits, researchers have devised a semi-automated process to build polymer scaffolds for guiding the development of three-dimensional heart tissue. The method, which entails layer-by-layer fabrication, will enable more precise investigation of the three-dimensional cues that drive cells to organize and form tissue...
Doctors have a new way of thinking about how to treat heart and skeletal muscle diseases. Body builders have a new way of thinking about how they maximize their power. Both owe their new insight to high-energy X-rays, a moth and cloud computing.
C.R. Bard today announced that it won a favorable ruling from the U.S. Patent & Trademark Office, which notified the medical device maker that it intends to uphold the patentability of the stent-graft patent at the heart of a long-running infringement lawsuit with W.L. Gore & Assoc.
TYRX, Inc. has announced that it has received FDA clearance to market the fully resorbable AIGISRx R Antibacterial Envelope for use with pacemakers and implantable cardioverter defibrillators (ICDs). The AIGISRx R Antibacterial Envelope received approval from Health Canada in January 2013.
On this episode of The Pulse, a device that helps train the brain to turn sounds into images, detecting cancer by imaging the consumption of sugar, biomedical applications for a new hydrogel, and a nanofiber mesh that treats tumors with both thermotherapy and chemotherapy.
If the heart following a heart attack is not sufficiently supplied with blood, heart tissue dies. In adult humans, the ability to heal itself is hardly developed. Scientists from the Max Planck Institute for Heart and Lung Research, together with U.S. colleagues, have now observed in the embryo of the zebrafish that muscle cells migrate from the undamaged atrium into the ventricle and thus significantly contribute to regeneration.
According to Millennium Research Group, the global authority on medical technology market intelligence, declines in isolated coronary artery bypass graft procedures in the United States and Europe will primarily be attributed to the increasing use of percutaneous coronary intervention, which is less invasive and offers shorter recovery times.
Putting medical devices on the network provides a large number of benefits, such as supporting telemedicine and the easy transfer of test results to electronic medical records (EMR) systems. However, putting these devices on a network also introduces a number of risks.
Vascular surgical device maker CryoLife announced a regulatory green light today with the FDA's pre-market approval of its Sologrip laser fiber optic delivery system. Sologrip is a disposable handset designed to be used during surgery to support a relatively new procedure called transmyocardial revascularization approved by the FDA to treat difficult heart conditions.
Next-generation hydrogels can form synthetic scaffolds to support the formation of replacement tissues and organs in the emerging area of regenerative medicine. Embedding peptides into the hydrogels stimulates the growth of essential microvascular networks to ensure a good blood supply.
In a study reported in the July 1, 2013 Angewandte Chemie, a group of University of Illinois bioengineers have found a way to strongly adhere hydrogels to hydrophobic silicone substrates, an innovation that provides a valuable new tool for microscale biotechnology.
Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced today that its ANCHOR post-market registry enrollment has surpassed its key milestone of 250 patients.
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices and implants, announced today that on July 5, 2013 it acquired the assets of Clinical Instruments International, Inc. for $1.1mm, or 1.7X 2012 sales. Clinical Instruments is based in Southbridge, MA and manufactures carotid shunts and embolectomy catheters.
The FDA recommended bumping blood access devices down from Class III to Class II regulatory status, based on mounting evidence that these implanted tubes, catheters and cannulae belong in a lower-risk category. The federal watchdog agency said there's enough safety and efficacy data to peel off a layer of regulatory oversight.
Early-stage device company Dallen Medical announced a 1st-in-man study of its Compressyn band, a breast-plate wire closure device designed to help stabilize patients after open heart surgery. After the sternum is cracked during open-heart surgery, patients require specialized wires to hold the cavity together.
Penumbra, Inc. Launches 5MAX™ ACE—the Newest Clot Extraction Device to Treat Acute Ischemic Stroke PatientsJuly 8, 2013 8:00 am | by Business Wire | News | Comments
Today, Penumbra, Inc. announced the launch and wide availability of the 5MAX™ ACE, a next generation clot extraction device that uses aspiration alone to engage and remove blood clots causing an acute ischemic stroke. “I’ve used every generation of device for clot removal since the early days, including most recently, the stent retriever devices,” said Blaise Baxter, MD, FRCPC, Director of Interventional Services at Erlanger Hospital.
"James Gandolfini absolutely may have survived if hotel personnel had used an AED when they found him," said Dr. Matthew Budoff, an associate professor of medicine at the David Geffen School of Medicine UCLA and a renowned cardiologist, during an interview.
Early-stage MitrAssist whizzed by it's hoped-for raise of $600,000, landing $1 million from angel and private investors in support of the company's mitral valve implant. MitrAssist, a spin-out of Tredline Group's accelerator program, is developing what it calls a "valve-on-valve" approach to treat mitral regurgitation for patients too elderly or unstable for an invasive open-heart operation.
To unlock the potential of more frequent therapy, medical devices must move out of the doctor’s office and travel with patients to their homes and offices. But, this great opportunity is not without its challenges. The same patient who stands to reap great benefit from a home medical device may instead endanger themselves by applying the device incorrectly.
Dallen Medical Initiates “First-in-Man” Clinical Study of its Compressyn™ Band Sternal Closure DeviceJuly 2, 2013 8:00 am | by Business Wire | News | Comments
Dallen Medical, an emerging medical device company, announced today that the first three patients have been treated using its proprietary Compressyn™ Band sternal closure device. The first Compressyn device used for stabilization and rigid fixation following open heart procedures was performed by Dr. Joseph Wilson of Eisenhower Medical Center.
As Parker sees it, the three biggest obstacles to [design] success for patient care products, such as oxygen concentrators and ventilators, are portability, battery life, and reliability. To make home care products more portable, Parker has reduced the size of some valves up to 75%.
As more therapies are able to indicate implantable devices for treatment, incorporating drug delivery into them can be a significant additional benefit. Even when drug delivery is the primary function, implantable devices can be preferable. This article reviews some representative applications that device designers can leverage in developing new products for the implantable drug delivery market.
ZOLL Medical Corporation has purchased the assets of CoAxia, an early revenue stage medical device company that provides catheter-based perfusion augmentation therapies to improve outcomes for patients with cerebral ischemia resulting from vasospasm, following subarachnoid hemorrhage.